Virtual Library
Start Your Search
Y. Lebowicz
Author of
-
+
P1.07 - Poster Session/ Small Cell Lung Cancer (ID 221)
- Event: WCLC 2015
- Type: Poster
- Track: Small Cell Lung Cancer
- Presentations: 1
- Moderators:
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P1.07-003 - Role of Tumor Infiltrating Lymphocytes in Small Cell Lung Cancer (ID 1486)
09:30 - 09:30 | Author(s): Y. Lebowicz
- Abstract
Background:
Small-cell lung cancer (SCLC), a histological subtype of lung cancers, carries a very poor prognosis. Female sex, performance status (PS), and stage are known prognostic markers for SCLC. Lymphocytes have been observed and described in SCLC biopsies from the lung. However, no information is available that defines the correlation of these lymphocytes to SCLC outcomes. To identify this correlation of TiLs to overall survival (OS) and progression free survival (PFS) in SCLC, we carried out a retrospective analysis of SCLC cases diagnosed at our hospital 2008-2013.
Methods:
53 patients’ biopsies of SCLC stained with hematoxylin and eosin were examined with light microscopy at 40X by in-house hematopathologist . Lymphocytes that were interspersed among the tumor cells were counted, and then obtained the pertinent data. Spearman rank correlation analysis was used to assess correlation.
Results:
Among the 53 patients 30 (57%) females and 23 (43%) male, age mean 62.87 years (35-89), average PS 1.53 (0-4), 99% of the patients Caucasian, TiLs mean 70 (10-400), 18 (34%) had LS-SCLC, and 35 (66%) had EX-SCLC Progression free survival (data available for total of 36 patient, of which 16 LS-SCLC, 20 ES-SCLC): LS-SCLC 20.84 months (95% CI; 13.76-27.92), ES-SCLC 5.7 months (95% CI; 4.17-7.23) OS: LS-SCLC 22.97 months (95% CI; 16.16-29.78), ES-SCLC 8.21 months (95% CI; 5.30-11.13) Correlation between TiLs and OS Spearman’s rho was calculated at 0.15, p=0.28; indicating no correlation between TiLs and OS. Correlation when stratified by stage: In LS-SCLC, no correlation between OS of LS-SCLC and number TiLs’s found (Spearman’s rho=0.19, p=0.45 for total of 18 patients). In ES-SCLC, no correlation between OS of ES-SCLC and TiLs (Spearman’s rho=-0.02, p=0.91).
Conclusion:
Recent data in breast cancer (1) and melanoma indicate the presence of TiLs is a positive prognostic marker. However, we were not able to find a positive or negative correlation of TiLs to SCLC outcomes. It is possible that small sample size failed to show a correlation. However, the known prognostic markers for SCLC i.e. female sex, PS, and stage of disease showed correlation with OS in our sample size (data not shown). This indicates that a) our sample size is a good representation of previously studied larger samples, and b) a likely accurate assessment of this correlation. Previously, Wang et al (3) has described FOXP3+ T cell lymphocytes as negative prognostic maskers for SCLC. However, our clinical data fails to provide additional support. Taken together, these studies advocate for larger sample size evaluation. References: 1)Loi et al. Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98. JCO September 20, 2014;32;2935-2937 2)Thomas et al. Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study. JCO November 20, 2013;31:4252-4259 3)Wang et al. Small cell lung cancer tumor cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP31 cells in tumor infiltrate. IJC April 24, 2012; 131:E928–E937
